期刊: HEPATOLOGY RESEARCH, 2022; 52 (7)
Aim Hepatocellular carcinoma (HCC) is common and causes many deaths worldwide. The aim of this study is to explore the mechanism by which long non-cod......
期刊: HEPATOLOGY RESEARCH, 2022; 52 (11)
Aim Surgical treatment is the first-line treatment for patients with Barcelona Clinic Liver Cancer (BCLC) stage 0 or A1 hepatocellular carcinoma (HCC)......
期刊: HEPATOLOGY RESEARCH, 2022; 52 (7)
Aim The present study was to evaluated the clinical value of anatomical thermal ablation to treat hepatocellular carcinoma compared with routine therm......
期刊: HEPATOLOGY RESEARCH, 2022; 52 (9)
Aim Tyrosine kinase inhibitors target transarterial chemoembolization (TACE)-mediated vascular endothelial growth factor to inhibit tumor revasculariz......
期刊: HEPATOLOGY RESEARCH, 2022; 52 (2)
Aim The global burden of chronic liver disease is substantial. Limited studies have reported the prevalence of metabolic dysfunction-associated fatty ......
期刊: HEPATOLOGY RESEARCH, 2022; 52 (8)
Aim Transarterial chemoembolization (TACE) combined with a PD-1 inhibitor and TACE combined with a PD-1 inhibitor and lenvatinib have recently been re......
期刊: HEPATOLOGY RESEARCH, 2022; 52 (6)
Aim To investigate the change of tumor feeding artery diameter and the efficacy of metastasis inhibition after transarterial chemoembolization (TACE) ......
期刊: HEPATOLOGY RESEARCH, 2022; 52 (4)
Aim To summarize HBV-related biomarkers predicting nucleos(t)ide analogs (NAs) discontinuation and hepatitis B virus (HBV) recurrence after drug withd......
期刊: HEPATOLOGY RESEARCH, 2022; 52 (6)
Background Hepatocellular carcinoma (HCC) is a type of primary liver cancer with high mortality. Circular RNAs (circRNAs) have been confirmed to be in......
期刊: HEPATOLOGY RESEARCH, 2022; 52 (3)
Aim Due to high invasion and metastasis, hepatocellular carcinoma (HCC) is known as one of the most fatal carcinomas. We aim to further investigate re......
期刊: HEPATOLOGY RESEARCH, 2021; 51 (6)
Aim To assess the role of consolidation therapy after cessation of nucleoside/nucleotide analogs (NAs) for off-treatment outcome and to explore the op......
期刊: HEPATOLOGY RESEARCH, 2021; 51 (6)
Aim The REACH and REACH-2 trials investigated ramucirumab versus placebo in patients with advanced hepatocellular carcinoma (HCC). Ascites is common i......
期刊: HEPATOLOGY RESEARCH, 2021; 51 (6)
Aim This study aimed to analyze the effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors on the indexes of liver fibrosis in patients with typ......